Bipolar Disorder Therapeutics Market Share

North America Market Insights

North America is a key player in the bipolar disorder therapeutics market, projected to register a significant share of 34.7% in 2035. The region benefits from a vast consumer base with rising mental health awareness and expanded treatment advancements. US. dominates the North America market, owing to the exceptional mental health funding and awareness campaigns that are undertaken. Besides, it is reported that the lithium prescribed to about 27% of bipolar disorder patients in 2022 with a slight upward trend through 2025, based on NLM report in July 2025. This contrasts with a slight decrease in antidepressant prescriptions during the same time.

Canada is another major contributor to growth in North America’s bipolar disorder therapeutics market, which is growing at a rapid pace. The existence of components such as provincial and federal healthcare systems is driving business in the country’s bipolar disorder sector. As per the government of Canada report in April 2023, government has allocated USD 200 million for Brain Canada, to improve the mental health status among the individuals an advance the therapies. Therefore, this wider market scope intends to support business in the sector.

Bipolar Disorder Cases in U.S. and Canada

Source: UTSWMED, August 2022, CMHA 2025

Asia Pacific Market Insights

Asia Pacific bipolar disorder therapeutics market is growing exponentially owing to the tremendous support from the region’s governments. Besides the rising mental health awareness among the population intended to fuel growth in this sector. Japan leads the Asia Pacific market spends 16.2 billion JPY in R&D of psychiatric disorders, as reported by JMA journal in January 2025. Besides, South Korea witnessed the adherence to the digital therapeutics push as stated by the MFDS in 2024.  Hence, the contribution from these major nations will readily bolster the market expansion by 2035.

India is a leading player in the bipolar disorder therapeutics industry, driven by the tremendous demand for advanced therapeutics. There is a huge patient pool affected by the mental health disorder, with nearly 70% to 92% of patients remaining untreated, showcasing health disparities in the country. Besides, NHM in 2024 reported that this rising prevalence has encouraged the governing bodies to invest in the sector with a substantial investment. Furthermore, there is an increase in lithium uptake, pushing therapeutic production in the country.

Europe Market Insights

Europe's bipolar disorder therapeutics market is driven by a stable population of diagnosed adults, expanded public payer coverage, and manufacturing and distribution centers throughout the EU and UK. Demand focuses on maintenance mood stabilizers and second-generation antipsychotics for bipolar depression and maintenance; aging populations and enhanced screening enhance treated prevalence. Public procurement and centralized HTA drive pricing and access to national formularies, and joint procurement mechanisms compress net prices while guaranteeing volume.

Germany is leading the bipolar disorder therapeutics market and is driven by high healthcare spending and advanced psychiatric care facilities. Germany has spent more than €1 million on mental health accounts for a growing share of the national healthcare budget, according to the NLM report published in June 2024. Improved government programs, universal access to new treatments, and increased awareness fuel sustained growth. Germany's robust pharmaceutical environment also confirms continued market expansion with bipolar disorder drugs.